Call for Abstract
12th World Pharma Congress, will be organized around the theme “Healthcare Policy-Makers And Payers: Key Concerns In Paradigm Shift Of Pharma Industry Trends”
Pharma Congress 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Pharma Congress 2017
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Disease is the enemy of mankind, which affects part or all of organism. Efforts to cure or improve the health condition against disease lead a remarkable improvement in pharmaceutical sciences. Pharmaceutical science is a wide range of combinations of scientific disciplines that contribute to the discovery and development of new drugs and therapies. Advancements in the branches of pharmaceutical sciences enhance the development of new reliable entities. Every aspect of the pharmaceutical science deals with the design, action, delivery, and disposition of drugs.
According to the 2015 EU Industrial R&D Investment Scoreboard the pharmaceutical and biotechnology sector amounts to 18.2% of total business R&D expenditure worldwide.On the other side Europe drug manufacturing is 225000 €millions and exports were 361500 €millions. Europe spent 31,500 €millions on R&D in 2015 while US spent 47,061€millions.
- Track 1-1Biopharmaceutics
- Track 1-2Physical Pharmaceutics
- Track 1-3Pharmacology
- Track 1-4Pharmacogenomics
- Track 1-5Bio informatics
- Track 1-6Pharmaceutical Microbiology and Sterilization
- Track 1-7Pharmacognocy
- Track 1-8Pharmaceutical Jurisprudence
- Track 1-9Organic and Inorganic Chemistry
- Track 1-10Pharmaceutical Botany
- Track 1-11Pharmacoepidemiology
- Track 1-12Biochemistry
Persistent innovative development is one of the eminent characters of pharmaceutical industry.Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage, giving rise to abundant but relatively dispersed knowledge of the mechanisms driving drug discovery and development. The invention of new medicines, and the improvement of existing drugs constitute the development firms in this industry. The occasional triumph of creating a novel therapy in an area with no prior treatments counts among the pharmaceutical industry’s most defining hallmarks.
Germany is forecast to have highest increase in market value at € 11.4bn. Novartis is forecast to reduce its R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20, Celgene and Regeneron are forecast to grow their R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022.
- Track 2-1 Nanotechnology
- Track 2-2Genomic Technologies
- Track 2-3Proteomic Technologies
- Track 2-4Synthetic Biology
- Track 2-5Quality by Design
- Track 2-6Random Screening
- Track 2-7Molecular Designing
- Track 2-8Drug Metabolites
- Track 2-9Challenges in Drug Discovery
- Track 2-10Criteria for Target Selection
- Track 2-11Advancements of In vitro studies
- Track 2-12Enhancements of In vivo studies
Pharmacotherapy deals in administering pharmaceutical drugs distinguishing from therapy using surgery, radiation, movement or other methods. Drug therapy complies patient care with various types of pharmaceutical drugs ensuring the safe, appropriate and economical use.
North America is expected to account for more than half the therapeutic drug monitoring market share in 2015. It is the prime market for therapeutic drug monitoring. The market in Europe on the other hand is growing at a slower rate. Therapeutic Drug Monitoring Market’s worth is expected 2.55 Billion USD by 2020 globally.
- Track 3-1Effective ways of Drug Therapy
- Track 3-2Adverse Effects in Drug Therapy
- Track 3-3Drug therapy problem for seamless monitoring (DTPsm)
- Track 3-4Drug Therapy Monitoring
- Track 3-5Therapeutic index
Clinical trials are the clinical investigation of a drug that administered or dispensed to, or used involving one or more human subjects. Clinical trials are the major parameter for the approval of drug, as they mainly deals with the effectiveness and safety. Clinical trials plays a vital role in the development of new drug entity as it subjected to various phases for approval . Advancements in clinical trials enhances the drug development process by means of reducing time duration, sometimes the cost.
The success rate of Phase II trials that proceed to Phase III, as of 2010, is 18%. The amount of money spent on Phase II/III trials in 2015 by Large Sponsors (R&D $500M+) was $465,725,000 on average, while Non-Large Sponsors (R&D <$500M) spent $13,352,000 on average. The entire process of a drug from lab to this point may take approximately 12 to 18 years (but not always), often costing over $1 billion.
- Track 4-1Role of Clinical Trials
- Track 4-2Goals of Preclinical studies
- Track 4-3Safety potential results of Preclinical studies
- Track 4-4Overcoming hurdles in Clinical Trials
- Track 4-5Meeting the requirements of FDA review process
- Track 4-6Safety and Effectiveness of Drug
To obtain a required therapeutic effect, type of formulation, technology and system for transporting drug are the important variables. Drug delivery technologies alters the drug release profiles, absorption, distribution, and elimination of product for the safety efficacy. Developing new avenues for drug delivery vehicles reported promising results. The practice of drug delivery has changed dramatically in the past few decades and even greater changes are anticipated in the near future.
- Track 5-1Nano Drug Delivery Systems
- Track 5-2Polymeric Drug Delivery Systems
- Track 5-3Drug Metabolites Novel Drug Delivery System
- Track 5-4Transdermal Drug Delivery System
- Track 5-5Protein-Protein Interactions as Drug Targets
- Track 5-6Recent Trends in Drug Delivery
Pharmaceutical formulations is extensive procedure involving characterization of a drug's physical, chemical, and mechanical properties in order to choose what other ingredients (excipients) should be used in the preparation and resulting a safe and efficacy product. Modern pharmaceutical formulation is expanding its sector with technology and innovation to formulate eminent result oriented formulations.
The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021 at a CAGR of 6.1% in the forecast period 2016 to 2021. The rising demand for new drug delivery systems, greater understanding of the functional benefits of excipients, growing pharmaceutical industry, and patent expiries of several blockbuster drugs are positively impacting the overall growth of the market.
- Track 6-1Drug selection
- Track 6-2Preformulation studies
- Track 6-3Types of Dosage forms
- Track 6-4Polymeric Drug Formulation
- Track 6-5Surface and Bulk Properties of Polymers
- Track 6-6Advances in improvement of formulations in Route of Administration
- Track 6-7Advanced Evaluations in Product Efficacy
- Track 6-8Nano-pharmaceutical formulations
- Track 6-9Pharmaceutical Devices
Drug development involves enormous methods and development procedure to attain therapeutic effective level. Emerging new Formulation is a persistent process with utilisation of abundant knowledge of pharmaceutics. Considering all characteristics of substances used, and their behaviour towards formulations need more innovative approach of drug development.
The global market value for drug development technologies market share was about 30% in 2015 valued at $18 billion followed by Bioanalytical Assays or instruments by about $14 billion. Innovative formulations are estimated to have contributed to 73%. To develop a new pharmaceutical formulation and to conduct clinical trials it cost at € 1,926 million in 2016.
- Track 7-1Innovative Therapeutic Studies
- Track 7-2Effect of Polymorphism in Pharmaceutical Drug Development
- Track 7-3Technical limitations in Drug Development
- Track 7-4Difficulties in Regulatory Approvals
- Track 7-5Financial constraints in Drug Development
Regulatory Affairs has a very specific meaning within the healthcare industries . It's regulations are for systematic manufacturing and marketing of safe, efficacious and qualitative drugs. Improving new regulations and adopting to the technology regulatory affairs set new goals and challenges to the pharmaceutical formulation .
The market is expected to expand at a substantial 11.5% CAGR from 2015 to 2023 and rise to a valuation of US$5.7 billion by 2023.
- Track 8-1Regulatory Affairs Filing and Documentation
- Track 8-2Enhancing Regulatory Science for Public Health
- Track 8-3Meeting the Challenges for Regulating
- Track 8-4Patent and types of Patent Application
- Track 8-5Copyrights
- Track 8-6Trademark
- Track 8-7Infringement
- Track 8-8Iprs and Market for Technology
- Track 8-9Role of Patent Co-operation Therapy
It deals with prevention of adverse drug reaction by collection, detection, assessment, monitoring. It concerns with the identifying hazards associated with pharmaceutical formulation. The advancement associated with pharmacovigilance helps in producing the valid formulation by focussing on the collected data from patients and health care providers.
Patient awareness regarding adverse drug events is stimulating global pharmacovigilance market growth by increase in number of national pharmacovigilance centers. Spain pharmacovigilance market size was valued over USD 230 million in 2015 and witness 10.2% CAGR from 2016 to 2024, to surpass USD 550 million by 2024.
- Track 9-1Adverse Event Reporting
- Track 9-2Risk Management Plans
- Track 9-3The Importance of Pharmacovigilance, Safety Monitoring of Medicinal Products
- Track 9-4Role of Pharmacovigilance Centres
- Track 9-5Ecopharmacovigilance (EPV: pharmacoenvironmentology)
GMP is Set of guidelines to manufacturers must meet to assure that the products are high quality and safe. GMP covers all aspects of production from the starting to end of the manufacturing aspects. Introduced latest trends in GMP are risk- based approaches which are to encourage adoption of new technology by pharmaceutical industry. Pharmaceutical industries are facing hurdles in adopting new technologies quickly.
- Track 10-1Good Manufacturing Practice in International Countries
- Track 10-2GMP Requirements & Medical devices
- Track 10-3cGMP Guidelines
- Track 10-4Technology in GMP and cGMP
- Track 10-5Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach
Pharmacy is a healthcare profession assisting individual in making the best use of medicine. Ethics are intended to state publicly the principles that form the fundamental basis of the roles and responsibilities of pharmacists.
Spending on specialty drugs in 2012 in the United States was about $87 billion. Estimates suggest that it could quadruple by 2020, reaching about $400 billion.
- Track 11-1Pharmacist in Relation to his Job
- Track 11-2Pharmacist in Relation to his Trade
- Track 11-3Pharmacist In Relation to his Medical Profession
Pharmacists are becoming a more integral part of the health care team. Pharmacists do indeed dispense medicines, but first they check for any possible interactions with other medicines or medical conditions. They also instruct patients on how to take the medicines and will inform them about what to do if certain side effects arise. Pharmacy is the healthcare service science and expertise of preparing and dispensing drugs. Pharmacy Modern service includes more traditional and advanced compounding and dispensing medication healthcare.The biggest challenge facing pharmacy is continuing to communicate its role, deliver its value, and be reasonably reimbursed.
the Bureau of Labor Statistics projects a slower-than-average 3 percent employment growth for pharmacists by 2024, with the field adding 9,100 new jobs. Employment of pharmacists is expected to decline slightly in traditional retail settings because more people are having their prescriptions filled online or through mail order.
- Track 12-1Challenges in Pharmacy Practise
- Track 12-2Role of Pharmacist in Patient Care
- Track 12-3Role of Pharmacist in the Future
- Track 12-4Future Vision and Challenges for Hospital Pharmacy
- Track 12-5Challenges in Pharmacy Supply of Medicine to the Provision of Care
- Track 12-6The Impact of Technology in Pharmacy
- Track 12-7Role of Pharmcay in Development and Needs of Patient Care
- Track 12-8Trends and Problems in Posology
- Track 12-9Role of Pharmacist as a Pharmacy Benefit Manager
Pharmacokinetic studies are more important for therapeutic biologics . Identifying the key factors that govern absorption, distribution, metabolism, and excretion of biologics as therapeutic agents improved the opportunities for the scientists working in drug disposition research field.
- Track 13-1Drug Absorption Methods
- Track 13-2Effect of pH on Drug Disposition
- Track 13-3Drug Distribution
- Track 13-4Drug Metabolism
- Track 13-5Drug Excretion
- Track 13-6Biologics and Biosimilars
- Track 13-7Buffers in Biologics Manufacturing
Producing safe and effective formulation is the main goal for Pharmaceutical industry. Hence pharmaceutical industry has great concern towards impurities due to their adverse effects. The trends in pharmaceutical analysis focuses on the modern methods, technology and tools for control of related impurities, and faster analysis time, better separation time and faster method development.
- Track 14-1Qualitative Analysis
- Track 14-2Quantitative Analysis
- Track 14-3Quality Control and Quality Assurance
- Track 14-4Validation Methods
A pharmaceutical company is a commercial business licensed to research, develop, market and/or distribute drugs, most commonly in the context of healthcare. The winds of change are blowing through and, in fact, revolutionizing logistics in the global pharmaceutical industry. The prime contributing factors are rising costs, growing risks, changing consumer needs and tightening regulations ,globally.
Pharmaceuticals represented a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US $400 bn by 2018, with the ten largest pharmaceutical companies collectively commanding about a third of the market.
- Track 15-1Role of Pharmaceutical Representatives
- Track 15-2Evaluation of Marketing
- Track 15-3Regulation and Fraud
- Track 15-4Cost Effectiveness of Medicines (Pharmacoeconomics)
Bio availability is the rate and extent of active drug absorbed and available for action . Assessment of “interchangeability” between the generic and the innovator product is carried out by a study of bioequivalence (BE). During formulation of new entities bio availability and bio equivalents are also prime parameters. Through the conduct of bioavailability and bioequivalence studies, Generic drug products results on average bioequivalence in drug absorption.
The top 15 biopharmaceutical products each profits annual revenue of more than $2 billion, with some drugs generating sales of more than $10 billion a year. In 2015 the top NMEs include Pfizer’s Ibrance, J&J’s Darzalex and Gilead’s Genvoya with a cumulative value of $32bn of sales expected in 2020.
- Track 16-1Physico - Chemical properties affecting Bioavailability
- Track 16-2Formulation Factors Aaffecting Bioavailability
- Track 16-3Pharmacokinetics
- Track 16-4Pharmacodynamics Studies
The life sciences sector’s growth correlates highly with countries’ general economic strength and health care spending levels, and both of these vary widely around the globe.
The life sciences sector’s growth correlates highly with countries’ general economic strength and health care spending levels, and both of these vary widely around the globe. In 2015 North America accounted for 48.7% of world pharmaceutical sales compared with 22.2% for Europe. According to IMS Health data, 58% of sales of new drug discovery made during the period 2010–2015 were on the US market, compared with 23% on the European market. Europe is ensuring competitive growth along with other countries. By 2022, products currently in drug development will account for 17% of sales in Europe. Europe is expected to show a 3% CAGR 2016-22, mainly driven by the launch of new products currently in development. The penetration of biotech products is set to increase from a 24% market share in 2015 to 29% in 2022.